naringenin

hesperetin conjugate profile in urine

no effect, n = 16

the profile of the conjugates of flavanones formed and excreted in urine is neither affected by the absorption site nor by a 3-fold change in dose

PMID:20100371 · one of two readings recorded this

plasma naringenin AUC

increases, p = 0.0001, n = 16

The area under the plasma-time curve of naringenin from (2) alpha-rhamnosidase-treated orange juice was increased about 4-fold (P < 0.0001)

PMID:20100371 · one of two readings recorded this

plasma naringenin Cmax

increases, p = 0.0001, n = 16

peak plasma concentration (Cmax) was 5.4-fold higher (P < 0.0001)

PMID:20100371 · one of two readings recorded this

plasma naringenin Tmax

decreases, p = 0.002, n = 16

Tmax was decreased from 311 to 92 min (P = 0.002)

PMID:20100371 · one of two readings recorded this

urinary excretion of naringenin, percent of dose

increases, p = 0.0001, n = 16

the amount in urine was increased from 7 to 47 % (P < 0.0001) of the dose

PMID:20100371 · one of two readings recorded this

relevant adverse events and blood safety markers

no effect, n = 18

There were no relevant AEs or changes in blood safety markers following ingestion of any of the naringenin doses

PMID:31468636 · one of two readings recorded this

NAFLD-related biological processes (energy balance, lipid and glucose metabolism, inflammation, oxidative stress)

modulates, n = 36

Of 1217 full-text articles assessed, 36 studies met the inclusion criteria

PMID:32879962 · one of two readings recorded this

antipyretic time

decreases, p = 0.02, n = 180

Antipyretic time (day) | 1.5 ± 0.2 | 3.8 ± 0.4 |.02

PMID:34310866 · one of two readings recorded this

baseline age

no effect, p = 0.56, n = 180

Age (years) | 2.7 ± 1.2 | 2.6 ± 1.0 |.56

PMID:34310866 · one of two readings recorded this

baseline body temperature

no effect, p = 0.81, n = 180

Temperature (℃) | 38.2 ± 2.5 | 38.4 ± 2.2 |.81

PMID:34310866 · one of two readings recorded this

baseline heart rate

no effect, p = 0.64, n = 180

Heart rate, number/min | 94 ± 6 | 95 ± 8 |.64

PMID:34310866 · one of two readings recorded this

bullae of lung (complication)

decreases, p = 0.04, n = 180

Bullae of lung | 2 (2.2) | 9 (10) |.04

PMID:34310866 · one of two readings recorded this

cough disappearance time

decreases, p = 0.03, n = 180

Cough disappearance time (day) | 3.7 ± 0.5 | 5.6 ± 0.6 |.03

PMID:34310866 · one of two readings recorded this

gastrointestinal bleed (complication)

decreases, p = 0.03, n = 180

Gastrointestinal bleed | 1 (1.1) | 11 (12.2) |.03

PMID:34310866 · one of two readings recorded this

lung rale disappearance time

decreases, p = 0.04, n = 180

Lung rale disappearance time (day) | 4.3 ± 1.2 | 6.5 ± 1.4 |.04

PMID:34310866 · one of two readings recorded this

proteinuria (complication)

decreases, p = 0.01, n = 180

Proteinuria | 3 (3.3) | 15 (16.7) |.01

PMID:34310866 · one of two readings recorded this

serum IL‐10

no effect, p = 0.33, n = 180

IL‐10 (ng/ml) | T0 | 14.0 ± 1.8 | 12.9 ± 3.2 |.33

PMID:34310866 · one of two readings recorded this

serum IL‐10

increases, p = 0.05, n = 180

T1 | 31.9 ± 4.6 * | 24.6 ± 8.4 * |.05

PMID:34310866 · one of two readings recorded this

serum IL‐10

increases, p = 0.04, n = 180

T2 | 43.7 ± 9.0 ** | 27.5 ± 8.9 * |.04

PMID:34310866 · one of two readings recorded this

serum IL‐10

increases, p = 0.03, n = 180

T3 | 51.2 ± 15.4 *** | 32.4 ± 6.7 ** |.03

PMID:34310866 · one of two readings recorded this

serum IL-6, IL-8, IL-10 and TNF-α by ELISA at T0-T3, symptom disappearance times and complication incidence in children with bronchial pneumonia

decreases, serum IL-6, IL-8 and TNF-α reduced more in the naringenin group than the azithromycin group at T1, T2 and T3 (p <.05)

Not recorded as a finding: the comparison was against another active treatment

Moreover, the serum levels of IL‐6, IL‐8, and TNF‐α in the NAR group showed more significant reduction at T1, T2, and T3 (p <.05), especially at T2 and T3, compared to the AZI group.

PMID:34310866 · one of two readings recorded this

serum IL-6, IL-8, IL-10 and TNF-α by ELISA at T0-T3; symptom disappearance times; complication and adverse reaction incidence, naringenin 5 mg/kg/day versus azithromycin 10 mg/kg/day for 5 days in children with bronchial pneumonia

decreases, serum IL-6, IL-8 and TNF-α reduced more in NAR group than AZI group

Not recorded as a finding: the comparison was against another active treatment

Moreover, the serum levels of IL‐6, IL‐8, and TNF‐α in the NAR group showed more significant reduction at T1, T2, and T3 (p <.05), especially at T2 and T3, compared to the AZI group.

PMID:34310866 · one of two readings recorded this

serum IL‐6

no effect, p = 0.87, n = 180

IL‐6 (ng/ml) | T0 | 78.4 ± 12.3 | 78.9 ± 11.7 |.87

PMID:34310866 · one of two readings recorded this

serum IL‐6

no effect, p = 0.14, n = 180

T1 | 64.9 ± 11.8 * | 72.1 ± 10.2 |.14

PMID:34310866 · one of two readings recorded this

serum IL‐6

decreases, p = 0.04, n = 180

T2 | 45.3 ± 9.1 ** | 68.3 ± 9.4 |.04

PMID:34310866 · one of two readings recorded this

serum IL‐6

decreases, p = 0.03, n = 180

T3 | 34.9 ± 8.2 *** | 53.5 ± 7.8 * |.03

PMID:34310866 · one of two readings recorded this

serum IL‐8

no effect, p = 0.69, n = 180

IL‐8 (ng/ml) | T0 | 62.4 ± 10.3 | 61.7 ± 10.3 |.69

PMID:34310866 · one of two readings recorded this

serum IL‐8

no effect, p = 0.28, n = 180

T1 | 42.9 ± 8.6 * | 57.1 ± 11.6 |.28

PMID:34310866 · one of two readings recorded this

serum IL‐8

decreases, p = 0.02, n = 180

T2 | 17.4 ± 3.3 *** | 50.4 ± 10.9 * |.02

PMID:34310866 · one of two readings recorded this

serum IL‐8

decreases, p = 0.04, n = 180

T3 | 15.3 ± 2.7 *** | 32.7 ± 10.9 ** |.04

PMID:34310866 · one of two readings recorded this

serum TNF‐α

no effect, p = 0.73, n = 180

TNF‐α (ng/ml) | T0 | 74.7 ± 16.3 | 73.9 ± 11.5 |.73

PMID:34310866 · one of two readings recorded this

serum TNF‐α

decreases, p = 0.04, n = 180

T1 | 42.9 ± 8.6 ** | 67.2 ± 12.3 |.04

PMID:34310866 · one of two readings recorded this

serum TNF‐α

decreases, p = 0.02, n = 180

T2 | 35.8 ± 5.1 ** | 55.7 ± 8.9 * |.02

PMID:34310866 · one of two readings recorded this

serum TNF‐α

decreases, p = 0.01, n = 180

T3 | 26.4 ± 3.6 *** | 51.6 ± 10.2 * |.01

PMID:34310866 · one of two readings recorded this

AST, ALT and NAFLD fibrosis score (NFS)

no effect, n = 44

However, there were no significant changes in AST, ALT and NFS

PMID:34516703 · one of two readings recorded this

AST, ALT and NAFLD fibrosis score

no effect, no significant changes

Not recorded as a finding: agentless sentence does not name the compound

However, there were no significant changes in AST, ALT and NFS.

PMID:34516703 · one of two readings recorded this

percentage of NAFLD grades (hepatic steatosis severity)

decreases, P < .001

Not recorded as a finding: no outcome node for ultrasound steatosis grade

Naringenin consumption significantly reduced percentages of NAFLD grades (P < .001), as well as, serum levels of triglyceride (TG) (P < .001), total cholesterol (TC) (P = .01), and low-density lipoprotein (LDL) (P = .02) and increased serum level of high-density lipoprotein (HDL) (P = .02) compared with the control group.

PMID:34516703 · both readings recorded this

percentages of NAFLD grades (hepatic steatosis severity)

decreases, p = 0.001, n = 44

Naringenin consumption significantly reduced percentages of NAFLD grades (P < .001)

PMID:34516703 · one of two readings recorded this

serum HDL

increases, p = 0.02, n = 44

increased serum level of high-density lipoprotein (HDL) (P = .02) compared with the control group

PMID:34516703 · one of two readings recorded this

serum LDL

decreases, p = 0.02, n = 44

low-density lipoprotein (LDL) (P = .02)

PMID:34516703 · one of two readings recorded this

serum total cholesterol

decreases, p = 0.01, n = 44

total cholesterol (TC) (P = .01)

PMID:34516703 · one of two readings recorded this

serum triglyceride

decreases, p = 0.001, n = 44

serum levels of triglyceride (TG) (P < .001)

PMID:34516703 · one of two readings recorded this

atherogenic index of plasma, non-HDL-C, TC/HDL-C, TG/HDL-C, LDL-C/HDL-C and non-HDL-C/HDL-C ratio

decreases, p = 0.05, n = 44

were significantly reduced in the intervention group, compared to the placebo group post intervention (P < 0.05)

PMID:34860705 · one of two readings recorded this

BMI and visceral fat level, naringenin versus placebo for 4 weeks in overweight/obese NAFLD patients

decreases, BMI reduced versus placebo, P = 0.001, p = 0.001

Not recorded as a finding: the supporting sentence never names the compound

Moreover, there was a significant reduction in BMI and visceral fat level in the intervention group when compared with the placebo group (P = 0.001 and P = 0.039, respectively).

PMID:34860705 · one of two readings recorded this

BMI

decreases, p = 0.001, n = 44

there was a significant reduction in BMI and visceral fat level in the intervention group when compared with the placebo group (P = 0.001 and P = 0.039, respectively)

PMID:34860705 · one of two readings recorded this

mean corpuscular hemoglobin concentration

increases, p = 0.05, n = 44

a marginally significant increase in the mean corpuscular hemoglobin concentration when compared with the placebo group (P = 0.050)

PMID:34860705 · one of two readings recorded this

mean corpuscular hemoglobin

increases, P = 0.023, p = 0.023

Not recorded as a finding: no outcome node for mean corpuscular hemoglobin

Mean corpuscular hemoglobin increased significantly in the naringenin group compared to the placebo group at the endpoint (P = 0.023).

PMID:34860705 · one of two readings recorded this

mean corpuscular hemoglobin

increases, p = 0.023, n = 44

Mean corpuscular hemoglobin increased significantly in the naringenin group compared to the placebo group at the endpoint (P = 0.023)

PMID:34860705 · one of two readings recorded this

systolic blood pressure, blood pressure

p = 0.055

Not recorded as a finding: marginal result (P = 0.055) with no significant direction; setting unspecified node would also be unbound

Furthermore, naringenin supplementation could marginally reduce systolic blood pressure (P = 0.055).

PMID:34860705 · one of two readings recorded this

systolic blood pressure

no effect, p = 0.055, n = 44

naringenin supplementation could marginally reduce systolic blood pressure (P = 0.055)

PMID:34860705 · one of two readings recorded this

visceral fat level, obesity-related parameter

decreases, P = 0.039, p = 0.039

Not recorded as a finding: no outcome node for visceral fat level

Moreover, there was a significant reduction in BMI and visceral fat level in the intervention group when compared with the placebo group (P = 0.001 and P = 0.039, respectively).

PMID:34860705 · one of two readings recorded this

visceral fat level

decreases, p = 0.039, n = 44

there was a significant reduction in BMI and visceral fat level in the intervention group when compared with the placebo group (P = 0.001 and P = 0.039, respectively)

PMID:34860705 · one of two readings recorded this

nitric oxide

decreases

NO (SMD - 3.97, 95% CI [- 5.50 to - 2.45]; I2 = 73.4%, p = 0.005)

PMID:35804246 · one of two readings recorded this

GSH

increases

GSH (SMD 4.58, 95% CI [1.64 to 7.51]; I2 = 90.5%, p < 0.001)

PMID:35804246 · one of two readings recorded this

MDA

decreases

MDA (SMD - 3.65, 95% CI [- 4.80 to - 2.51]; I2 = 69.4%, p = 0.001)

PMID:35804246 · one of two readings recorded this

TNF-α

decreases

TNF-α (SMD - 5.10, 95% CI [- 6.34 to - 3.86]; I2 = 74.7%, p < 0.001)

PMID:35804246 · one of two readings recorded this

IFN-γ

decreases

IFN-γ (SMD - 6.18, 95% CI [- 8.73 to - 3.62]; I2 = 53.7%, p = 0.115)

PMID:35804246 · one of two readings recorded this

IL-6

decreases

IL-6 (SMD - 5.84, 95% CI [- 7.83 to - 3.85]; I2 = 86.5%, p < 0.001)

PMID:35804246 · one of two readings recorded this

CAT

increases

CAT (SMD 4.19, 95% CI [1.33 to 7.06]; I2 = 79.9%, p = 0.007)

PMID:35804246 · one of two readings recorded this

GPx

increases

GPx (SMD 9.65, 95% CI [2.56 to 16.74]; I2 = 86.6%, p = 0.001)

PMID:35804246 · one of two readings recorded this

IL-1β

decreases

IL-1β (SMD - 4.23, 95% CI [- 5.09 to - 3.37]; I2 = 0.0%, p = 0.462)

PMID:35804246 · one of two readings recorded this

inflammatory and oxidative-stress markers (TNF-α, IL-6, IL-1β, IFN-γ, NF-κB, NO, CAT, SOD, GPx, GSH, MDA) pooled as SMD in animal autoimmune-disease models; sample matrix and assay not stated in abstract

no effect, SOD activity SMD 1.89, 95% CI [- 1.11 to 4.89]

Not recorded as a finding: the paper never states the instrument the node requires

However, treatment with naringenin showed no statistically difference in SOD activity (SMD 1.89, 95% CI [- 1.11 to 4.89]; I2 = 93.6%, p < 0.001).

PMID:35804246 · one of two readings recorded this

NF-κB

decreases

NF-κB (SMD - 3.77, 95% CI [- 6.03 to - 1.51]; I2 = 80.1%, p = 0.002)

PMID:35804246 · one of two readings recorded this

SOD activity

no effect

SOD activity (SMD 1.89, 95% CI [- 1.11 to 4.89]; I2 = 93.6%, p < 0.001)

PMID:35804246 · one of two readings recorded this

MDA

decreases

while improving antioxidant defenses (SOD, GSH) and reducing oxidative stress (MDA)

PMID:40996618 · one of two readings recorded this

TNF-α

decreases

levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22)

PMID:40996618 · one of two readings recorded this

IL-6

decreases

levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22)

PMID:40996618 · one of two readings recorded this

IL-17

decreases

levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22)

PMID:40996618 · one of two readings recorded this

arthritis severity score

decreases

Naringenin significantly reduced arthritis severity (SMD = - 3.50), paw volume (SMD = - 1.78)

PMID:40996618 · one of two readings recorded this

cartilage-degrading enzymes MMP-3, MMP-9

decreases

It also improved histopathology and body weight, and decreased cartilage-degrading enzymes (MMP-3, MMP-9)

PMID:40996618 · one of two readings recorded this

cytokine levels (TNF-α, IL-6, IL-1β, IL-17), arthritis score, paw volume, oxidative stress markers (SOD, GSH, MDA) pooled as SMD in rodent arthritis models; sample matrix and assay not stated in abstract

decreases, TNF-α SMD = - 4.94

Not recorded as a finding: the paper never states the instrument the node requires

Naringenin significantly reduced arthritis severity (SMD = - 3.50), paw volume (SMD = - 1.78), and levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22), while improving antioxidant defenses (SOD, GSH) and reducing oxidative stress (MDA).

PMID:40996618 · one of two readings recorded this

histopathology and body weight

increases

It also improved histopathology and body weight, and decreased cartilage-degrading enzymes (MMP-3, MMP-9)

PMID:40996618 · one of two readings recorded this

IL-1β

decreases

levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22)

PMID:40996618 · one of two readings recorded this

paw volume

decreases

Naringenin significantly reduced arthritis severity (SMD = - 3.50), paw volume (SMD = - 1.78)

PMID:40996618 · one of two readings recorded this

SOD and GSH (antioxidant defenses)

increases

while improving antioxidant defenses (SOD, GSH) and reducing oxidative stress (MDA)

PMID:40996618 · one of two readings recorded this

TNF-α, IL-6, IL-1β and IL-17 levels, SOD, GSH and MDA, arthritis score and paw volume in rodent rheumatoid arthritis models, pooled SMD

decreases, TNF-α SMD = - 4.94

Not recorded as a finding: the paper never states the instrument the node requires

Naringenin significantly reduced arthritis severity (SMD = - 3.50), paw volume (SMD = - 1.78), and levels of TNF-α (SMD = - 4.94), IL-6 (SMD = - 2.97), IL-1β (SMD = - 5.55), and IL-17 (SMD = - 1.22), while improving antioxidant defenses (SOD, GSH) and reducing oxidative stress (MDA).

PMID:40996618 · one of two readings recorded this